Inhibikase Therapeutics (IKT) EPS (Basic) Growth (1y) (2021 - 2026)
Inhibikase Therapeutics (IKT) EPS (Basic) Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 29.25% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17,151.81% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 61.34% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -7.74% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 88.81% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Inhibikase Therapeutics | 55.25 Mn | -115.12 Mn | - | 36.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36.50% |
| Dec 31, 2025 | 59.94% |
| Sep 30, 2025 | 78.94% |
| Jun 30, 2025 | 82.64% |
| Mar 31, 2025 | 78.46% |
| Dec 31, 2024 | 33.97% |
| Sep 30, 2024 | 25.08% |
| Jun 30, 2024 | 41.78% |
| Mar 31, 2024 | 27.14% |
| Dec 31, 2023 | 19.96% |
| Sep 30, 2023 | 17.22% |
| Jun 30, 2023 | -8.25% |
| Mar 31, 2023 | 5.95% |
| Dec 31, 2022 | 37.67% |
| Sep 30, 2022 | -1.76% |
| Jun 30, 2022 | 14.59% |
| Mar 31, 2022 | 29.79% |
| Dec 31, 2021 | -87.53% |
| Sep 30, 2021 | -117.41% |
| Jun 30, 2021 | -317.64% |